Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIRISE-02
- Development stage
- Preclinical
- Lead developer
- PDX Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
AIRISE-02 is a preclinical nanoparticle-based cancer immunotherapy developed by PDX Pharma. It uses a polymer-coated mesoporous silica Pdx-NP nanoparticle to co-deliver a CpG oligodeoxynucleotide TLR9 agonist and small interfering RNA directed against STAT3 into locally injected tumors. CpG activates antigen-presenting cells, while STAT3 silencing is intended to reduce tumor-cell survival and immunosuppressive signaling in the tumor microenvironment, enabling in situ tumor vaccination and systemic CD8-positive T-cell-mediated antitumor immunity. The program is in IND-enabling development for solid tumors. ([pdxpharm.com](https://www.pdxpharm.com/airise/))
- Brand names
- AIRISE™
- Other names
- Augmenting Immune Response and Inhibiting Suppressive Environment of tumors
02
Targets
TLR9 (Toll-like receptor 9)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on AIRISE-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIRISE-02.